A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Restless Leg Syndrome Due to Uraemia

Interventions

DRUG

Dipyridamole 50mg tid

Participants will take dipyridamole daily (50mg each time, three times a day) for 6 months

Trial Locations (1)

First Affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors

lead

Yunfeng Xia

OTHER

NCT07199504 - A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole | Biotech Hunter | Biotech Hunter